| GILD |
Gilead Sciences, Inc. |
72%
|
ticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report. The risk factors denoted with a "*", if any, are newly added or hav… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from CABA graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CABA graph: Reciprocal relationship from GILD g… |
| KYTX |
Kyverna Therapeutics, Inc. |
72%
|
Reciprocal relationship from KYTX graph: Reciprocal relationship from CABA graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other agains… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from CABA graph: and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require a… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require additional discovery research and then preclinical and clinical development. In add… |
| CABALETTA-BIO-GMBH |
CABALETTA-BIO-GMBH |
62%
|
disclosures Cash paid for interest $ 877 $ 208 Right-of-use assets obtained in exchange for finance lease obligations $ 4,841 $ 14,930 The accompanying notes are an integral part of these unaudited c… |
| CO-LLC |
CO-LLC |
62%
|
of our research and development activities, which are directed toward identifying and developing product candidates. We expense all research and development costs in the periods in which they are inc… |
| COMPANY-LLC |
COMPANY-LLC |
62%
|
of our research and development activities, which are directed toward identifying and developing product candidates. We expense all research and development costs in the periods in which they are inc… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
esources, continue to engage outside consultants, and maintain a detailed work plan to assess and document the adequacy of internal control over financial reporting. Additionally, we will enhance con… |
| LONZA-HOUSTON-INC |
LONZA-HOUSTON-INC |
62%
|
facilities or any other development or commercialization partner for the manufacture of product candidates; 46 • delays in having patients complete participation in a trial or return for post-treatme… |
| MINARIS-ADVANCED-THERAPIES-LLC |
MINARIS-ADVANCED-THERAPIES-LLC |
62%
|
facilities or any other development or commercialization partner for the manufacture of product candidates; 46 • delays in having patients complete participation in a trial or return for post-treatme… |
| NANJING-IASO-BIOTHERAPEUTICS-CO-LTD |
NANJING-IASO-BIOTHERAPEUTICS-CO-LTD |
62%
|
ludes Section 851, commonly referred to as the “BIOSECURE Act.” The BIOSECURE Act restricts U.S. government agencies from procuring biotechnology equipment or services from, or entering into contract… |
| NOVARTIS-PHARMACEUTICALS-CORPORATION |
NOVARTIS-PHARMACEUTICALS-CORPORATION |
62%
|
ticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report. The risk factors denoted with a "*", if any, are newly added or hav… |
| NVS |
Novartis AG |
62%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from CABA graph: ticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quar… |
| PRESENTATION-CABALETTA-BIO-INC |
PRESENTATION-CABALETTA-BIO-INC |
62%
|
disclosures Cash paid for interest $ 877 $ 208 Right-of-use assets obtained in exchange for finance lease obligations $ 4,841 $ 14,930 The accompanying notes are an integral part of these unaudited c… |
| TYCHO-THERAPEUTICS-INC |
TYCHO-THERAPEUTICS-INC |
62%
|
disclosures Cash paid for interest $ 877 $ 208 Right-of-use assets obtained in exchange for finance lease obligations $ 4,841 $ 14,930 The accompanying notes are an integral part of these unaudited c… |
| UK-LIMITED |
UK-LIMITED |
62%
|
ay 2026. Based on the safety profile observed at the lowest dose, multiple additional patients have been enrolled at a higher dose cohort in the RESET-PV trial ® and longer-term data at the higher do… |
| USA-LLC |
USA-LLC |
62%
|
of our research and development activities, which are directed toward identifying and developing product candidates. We expense all research and development costs in the periods in which they are inc… |
| WUXI-ADVANCED-THERAPIES-INC |
WUXI-ADVANCED-THERAPIES-INC |
62%
|
ay 2026. Based on the safety profile observed at the lowest dose, multiple additional patients have been enrolled at a higher dose cohort in the RESET-PV trial ® and longer-term data at the higher do… |
